BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 4, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Onkure's PI3Kα H1047R inhibitor OKI-219 cleared to enter clinic for solid tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Onkure's PI3Kα H1047R inhibitor OKI-219 cleared to enter clinic for solid tumors
Jan. 5, 2024
No Comments
Onkure Inc. has received FDA clearance of its IND application for OKI-219, a mutant selective PI3Kα H1047R inhibitor, for solid tumors.
BioWorld Science
Regulatory
Cancer
FDA
IND
